Artificial intelligence reads brain scans to detect deadly tumors

NCT ID NCT07664254

Completed Diagnosis Sponsor: Deep Learning Institute of Radiological Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an artificial intelligence system called GliomaAI-MG that analyzes routine MRI scans to detect a specific aggressive brain tumor type called molecular glioblastoma. Researchers used existing MRI data from 1,372 patients across 13 hospitals. The goal was to see how accurately the AI could identify these tumors compared to standard biopsy results. No new scans or treatments were given to patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GliomaAI-MG (Software as Medical Device)
What this could lead to: If successful, this AI could help doctors quickly identify aggressive brain tumors from standard MRI scans, speeding up diagnosis and treatment planning.
What could go wrong: This is an early, observational study using old data, not a real-world test. The AI may not work as well in different hospitals or with new patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOM WHO GRADE 4 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer disease glioblastoma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOM WHO GRADE 4 GLIOMA GLIOMA (DIAGNOSIS)

Contacts and locations

Locations

Deep Learning Institute of Radiological Sciences

Mumbai, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.